UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among […]
More Stories
How to Get Bot Lobbies in Fortnite? (2025 Guide)
Skills, strategies, and reflexes are important parts of the game. Still, some people would just break from all competition and...
NVIDIA Co. (NASDAQ:NVDA) Shares Sold by Point72 Italy S.r.l.
Point72 Italy S.r.l. reduced its stake in NVIDIA Co. (NASDAQ:NVDA – Free Report) by 66.7% during the 4th quarter, according...
Joe Burrow Biography: Girlfriend, Career, Injuries & Controversies
Cincinnati Bengals Quarterback, Joe Burrow isn’t just an amazing football player but is an inspiration for his fans. His life...
2025 Smartphone Market Surprises as a Dark Horse Claims Top Spot
The first Quarter of 2025 gave the Global Smartphone Market another facet to analyze. As an unexpected top seller is...
Hacks Finale: A Heartfelt Goodbye and a Glimpse Into the Future
After four seasons, Hacks has finally wrapped up. The season 4 Hacks finale “Heaven”, marks a considerable turning point for...
NVIDIA (NASDAQ:NVDA) Price Target Raised to $175.00 at TD Cowen
NVIDIA (NASDAQ:NVDA – Free Report) had its price objective lifted by TD Cowen from $140.00 to $175.00 in a report...